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Background: Ciliary neurotrophic factor (CNTF) expression is repressed in astrocytes by neuronal contact in the
CNS and is rapidly induced by injury. Here, we defined an inhibitory integrin signaling pathway.
Results: The integrin substrates laminin, fibronectin and vitronectin, but not collagen, thrombospondin or
fibrinogen, reduced CNTF expression in C6 astroglioma cells. Antibodies against αv and β5, but not α6 or β1,
integrin induced CNTF. Together, the ligand and antibody specificity suggests that CNTF is repressed by αvβ5
integrin. Antibodies against Thy1, an abundant neuronal surface protein whose function is unclear, induced CNTF in
neuron-astrocyte co-cultures indicating that it is a neuroglial CNTF repressor. Inhibition of the integrin signaling
molecule Focal Adhesion Kinase (FAK) or the downstream c-Jun N-terminal kinase (JNK), but not extracellular
regulated kinase (ERK) or p38 MAPK, greatly induced CNTF mRNA and protein expression within 4 hours. This
selective inhibitory pathway phosphorylated STAT3 on its inhibitory ser-727 residue interfering with activity of the
pro-transcription Tyr-705 residue. STAT3 can activate CNTF transcription because it bound to its promoter and FAK
antagonist-induced CNTF was reduced by blocking STAT3. Microinjection of FAK inhibitor directly into the brain or
spinal cord in adult mice rapidly induced CNTF mRNA and protein expression. Importantly, systemic treatment with
FAK inhibitors over 3 days induced CNTF in the subventricular zone and increased neurogenesis.
Conclusions: Neuron-astroglia contact mediated by integrins serves as a sensor to enable rapid neurotrophic
responses and provides a new pharmacological avenue to exploit the neuroprotective properties of endogenous
CNTF.
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Endogenous CNTF regulates the development of oligo-
dendrocytes [1] and some neurons [2], synaptic function
[3], and adult CNS neurogenesis [4,5]. CNTF treatment is
neuroprotective in many animal models [6-10], and pro-
motes retinal ganglion cell regeneration [11,12] and
remyelination [13]. Even so, clinical trials failed due to low
penetration of CNTF into the CNS and systemic side ef-
fects after subcutaneous injections [14]. CNTF is almost
exclusively expressed in the nervous system, suggesting* Correspondence: theo.hagg@louisville.edu
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reproduction in any medium, provided the orthat its pharmacological induction might solve these prob-
lems. In the CNS, CNTF is produced at very low levels
primarily by astrocytes [15] but little is known about
mechanisms that regulate its expression. We found that a
cAMP-reducing dopamine D2 agonist induces CNTF in
the brain but not the spinal cord [5], indicating the need
to find more universal regulation mechanisms.
The expression of CNTF is rapidly and robustly in-
duced in astrocytes upon brain injury [16] and stroke
[17], where it serves a neuroprotective role [18], as it
does in an experimental autoimmune encephalomyelitis
(EAE) model [19] and the retina [20]. We found that glial
CNTF is repressed by integrins and, conversely, that loss
of neuron-astroglial interaction increases CNTF in vitroLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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neuronal loss [18].
Integrins are a group of 24 heterodimer receptors with
alpha and beta subunits binding extracellular matrix
(ECM) proteins as adhesion partners [21]. The neuronal li-
gands that bind astroglial integrins to regulate CNTF are
unknown. Neurons do not make most of the classical
ECM molecules although they express laminin isoforms
[22,23]. Thy-1, whose function is unknown, is highly ex-
pressed by adult neurons [24] and is a ligand of αvβ3 [25]
and αvβ5 integrins [26] which are expressed by astrocytes
and astroglioma cells [27,28]. Integrins signal through focal
adhesion kinase (FAK) which can signal downstream to
the ERK, p38 and JNK pathways [29]. The intracellular sig-
naling pathways that regulate CNTF are unknown. The
transcription factor Sox-10 regulates CNTF expression in
Schwann cells [30] but is not present in astrocytes [31].
IL6 and CNTF itself induce CNTF expression [12,18],
suggesting a potential role of STAT3, which is downstream
of their gp130 receptor [32,33].Figure 1 CNTF is repressed by ECM and specific αvβ5 integrin and ne
laminin (LAM), fibronectin (FN1) and vitronectin (VTN) had lower levels of C
quantified by qRT-PCR. Fibrinogen (FG), thrombospondin (TSP), and collage
this suggests that a limited number of integrins repress CNTF. B) Neutralizi
expression relative to IgG (Ctrl) in C6 cells after 4 hours. Antibody selection
subunit is only found in αvβ5. C) Neutralizing antibody against Thy-1, an α
neuron co-cultures compared to IgG (Ctrl). Data represent means (± SEM) o
expressed relative to controls.We set out to identify the CNTF-repressing signaling
pathway from neuronal ligand to astroglial transcription
factor, and whether its pharmacological inhibition would
increase functional CNTF using adult SVZ neurogenesis
as an outcome measure.
Results
Glial CNTF is repressed through αvβ5 integrin
To identify which integrins repress CNTF, we first tested
various ECM ligands with known differential integrin
binding partners [21,34,35] in rat C6 astroglioma cells
which express CNTF [36]. The advantage of the C6 cell is
the purity, consistency and ease of the cultures compared
to primary astrocytes. Moreover, the low CNTF expres-
sion by C6 cells makes them a good cell model to study
changes in CNTF expression whereas the very high levels
in cultured primary astrocytes combined with the half-life
of 7 hours of the CNTF mRNA make it more difficult to
detect modest changes under acute conditions. CNTF
mRNA was decreased by ~25% when cells were cul-uronal Thy-1 ligand. A) C6 astroglioma cells grown for 4 h on
NTF mRNA compared to poly-d-lysine control (Ctrl, set at 1.00) as
n (COL) had no significant effect. Because of the binding specificity
ng antibodies against αv or β5, but not α6 or β1 induce CNTF mRNA
was guided by elimination of unlikely candidates (Table 1). The β5
vβ5 ligand, induces CNTF mRNA expression in primary astrocyte-
f 3–4 (A) or 6 (B, C) independent experiments and are fold changes
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(Figure 1A). CNTF expression was not affected by fibrino-
gen, thrombospondin and collagen. We therefore excluded
their integrin binding partners from further study (α1β1,
α2β1, α3β1, α4β1, α5β1, α10β1, α11β1, and αvβ3; Table 1).
We also excluded leukocyte-specific integrins from further
consideration (Table 1) as well as α7, α8, β6 whose pres-
ence in astrocytes is currently unknown (Pubmed search).
Finally, we did not test β8 antibodies as mature astrocytes
have down-regulated αvβ8 integrin [37] and we could not
obtain a suitable function-blocking antibody against rat.
Having narrowed down potential integrins that might
affect CNTF expression, function blocking antibodies were
used against α6, αv, β1 and β5 integrin subunits. Freshly
plated C6 cells incubated for 4 hours with αv and β5 in-
tegrin antibodies had 28% and 38% more CNTF mRNA,Table 1 Process to define which integrins repress CNTF
Integrin FG TSP COL LAM
α1β1 i, ii, iii i, ii, iii
α2β1 i, iii i, ii, iii i, ii, iii




α6β1 iii i, ii, iii
α6β4 i, ii, iii




α11β1 i, ii, iii
αvβ1






αmβ2 i, ii, iii
αxβ2 i, ii, iii iii
αEβ7
αIIbβ3 i, ii, iii i, ii, iii
We applied the following process to help us to decide which subunit blocking antib
appears in a row, that specific integrin is considered unlikely to be involved in repr
(Figure 1A) and the known integrin binding partners to eliminate potential integrin
and collagen (COL) had no significant effect on CNTF mRNA levels in C6 cells, as in
the cells indicate the following articles that list the specific ligand – integrin relation
Laminin (LAM), vitronectin (VTN), and fibronectin (FN) significantly reduced CNTF ex
further help with antibody selection, we eliminated all leukocyte-specific integrins [
results from the antibody experiment (Figure 1B) were used to eliminate a number
three candidates which potentially repress CNTF (“bold” letters in the last column).respectively, compared to no antibody or purified isotype
specific IgG (Figure 1B). In contrast, α6 and β1 integrin
antibodies did not significantly alter CNTF expression.
Interestingly, the only integrin with a β5 subunit is αvβ5,
suggesting that it may be specifically involved in inhibiting
CNTF expression.Astroglial CNTF is repressed by neuronal Thy-1
The surface protein Thy-1 is enriched in neurons through-
out the CNS [40,41] and binds αvβ5 integrin [25], but its
role in the brain is unknown. Primary cortical neurons
were incubated with Thy-1 blocking or IgG control anti-
bodies prior to seeding onto primary astrocyte monolayers.
Thy-1 antibody increased CNTF expression by ~40%




i, ii, iii X β1
i, ii, iii X








ii i, ii, iii β1
i, ii, iii i, ii, iii
i, ii, iii ii αv, β5







i, ii, iii i, ii, iii
odies to test and which integrins most likely repress CNTF. When “italics”
essing CNTF. We first used the data from the ECM substrate experiment
s involved in repressing CNTF. Thus, fibrinogen (FG), thrombospondin (TSP),
dicated by “italics” in the row of their known integrin partners. The numbers in
ship: i) Humphries et al., [34] ii) Plow et al. [38], and iii) Takada et al., [39].
pression, as indicated by “bold” numbers in the respective columns. Next, to
21]) as they are not present on glial cells (second to last column). Lastly, the
of β1- and α6-containing integrins (“italics” letters in the last column), leaving
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antibodies against laminin because the integrin binding
motif is unknown. Vitronectin [42] and fibronectin [43]
are not present in neurons.Glial Focal Adhesion Kinase represses CNTF mRNA
and protein
FAK is the best-known kinase associated with integrin sig-
naling [29,44]. C6 cells incubated with the FAK antagonist
(FAKi) PF573228 for 4 hours showed a more than 3 fold
induction of CNTF mRNA expression (Figure 2A). FAK
activity was clearly decreased by the inhibitor as assessed
by western blotting for phosphorylated FAK (Tyrosine-
397, here on pFAK; Figure 2B). In the same protein
extracts, CNTF was robustly increased by the inhibitor
(Figure 2C). Wounding the C6 cells by mechanical
dissociation induced CNTF expression within 2 hours
(Figure 2D). CNTF mRNA levels returned to baseline
after 6 hours despite similar cell survival between 2 and
6 hours (as defined by MTT assay and trypan blue counts;
data not shown). This suggests that both induction and
repression of CNTF occur rapidly. FAK inhibition of in-
jured cells did not cause further increases in CNTFFigure 2 FAK inhibition induces CNTF expression in vitro. A) C6 cells in
of CNTF mRNA compared to vehicle-only cultures (Ctrl). B) The inhibitor re
phosphorylated FAK (pFAK tyr-397). C) CNTF protein was also increased in
disinhibition. Blots are representative of 4 independent observations. D) C6
within 2 hours which was lost by 6 hours. E) FAK inhibition did not augme
change compared to controls and are shown as average +/− SEM. In A, n =mRNA (Figure 2E), suggesting that modulation of FAK
plays a central role in the injury-induced disinhibition of
CNTF. These experiments identified FAK as a molecu-
lar target to pharmacologically increase CNTF protein
expression.FAK-JNK activation mediates repression of CNTF
Downstream targets of FAK include ERK [45], JNK
[46,47] and p38 MAPK [48]. Pharmacological inhibition
of JNK induced CNTF mRNA expression in C6 as-
troglioma cells more than 3 fold, whereas antagonists of
ERK or p38 did not significantly alter CNTF expression
(Figure 3A). Moreover, FAK inhibitor treatment inac-
tivated JNK as shown by a reduction in phosphorylated
JNK (pJNK) protein (Figure 3B). These data indicate that
integrin-mediated CNTF repression occurs through a spe-
cific FAK-JNK signaling pathway.FAK represses CNTF by inhibiting STAT3 through the ser-
727 residue
Activation of STAT3 transcriptional activity depends upon
phosphorylation at a tyrosine residue (Tyr-705) [49,50].
STAT3 is inhibited by phosphorylation of a serine residuecubated for 4 hours with FAK inhibitor PF573228 have increased levels
duced FAK activity as shown in Western blots by the reduced levels of
the same protein extracts, showing the rapid and robust nature of the
cell injury by mechanical dissociation robustly induced CNTF mRNA
nt the dissociation-induced CNTF mRNA up-regulation. Data are fold
6, D and E, n = 4.
Figure 3 A specific intracellular FAK-JNK signaling pathway
represses CNTF. A) Incubation of C6 cells with inhibitors of JNK,
but not p38 or ERK, for 4 hours, increases CNTF mRNA compared to
vehicle controls (Ctrl). Data are means +/− SEM and are from 4
independent experiments. B) Incubation with FAK inhibitor reduced
JNK activation as shown by reduced JNK phosphorylation in western
blots, which are representative of 4 independent observations.
Antibodies against total JNK were used as internal controls.
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bitor had decreased STAT3 (Ser-727) phosphorylation
(Figure 4A) in the same extracts as the reduction of JNK
phosphorylation was shown (Figure 3B). Stattic is a select-
ive inhibitor that blocks STAT3 (Tyr-705) phosphorylation,
as well as STAT3 dimerization and translocation to the nu-
cleus [52]. Incubation of stattic 1 hour prior to treatment
with FAK inhibitor reduced CNTF mRNA expression 2
fold compared to FAK inhibitor alone suggesting that FA
Ki interferes with STAT3-stimulated CNTF expression
(Figure 4B). Conversely, co-incubation with an inhibitor of
the transcription factor AP-1 failed to affect FAK inhibitor
induced CNTF. Our bioinformatics analyses showed that
the CNTF promoter ([53]; Rat genome V3.4 Assembly; C6
cells are rat-derived) has a conserved STAT3 binding do-
main TTTCCTGGGA (Transcription Factor Encyclopedia,
[http://www.cisreg.ca]; Motifmap, [http://motifmap.ics.uci.
edu]) starting 25 nucleotides upstream of the CNTF initi-
ation point. We also found a consensus sequence at −1954
nucleotides (TTCTGGGAA); [54]. Chromatin immuno-
precipitation (ChIP) analyses in C6 cells confirmed that
STAT3 binds to genomic DNA containing the CNTF pro-
moter (Figure 4C). DNA sequencing of PCR-amplifiedproduct after the pull-down with the STAT3 antibody
showed the expected CNTF gene sequence (Figure 4D).
FAK modulates the CNTF-stimulating gp130-STAT3
Tyr-705 pathway
To determine the functional relevance of a second import-
ant STAT3 phosphorylation site (Tyr-705), which is down-
stream of gp130-containing receptors and can stimulate
cytokine expression [55-57] reviewed in [58], we incu-
bated C6 cells with CNTF, IL-6 or LIF. Robust phosphor-
ylation of STAT3 (Tyr-705) was observed as early as
15 minutes (Figure 4E middle row) and at 4 hours by IL-6
(~19 fold by densitometry; p < 0.001) with lesser induction
by CNTF (1.6 fold, p < 0.05) and LIF (~3 fold; p < 0.01)
relative to vehicle-treated control cells (data not shown).
In contrast, phosphorylation of STAT3 (Ser-727) was not
affected (Figure 4E, top row). These neural cytokines also
did not affect total STAT3 levels (Figure 4E, lower row).
Intriguingly, only IL-6 induced CNTF mRNA expression
after 4 hours and only by ~10% (Figure 4F; p < 0.05). This
raised the possibility that the inhibitory FAK pathway
largely overrides the CNTF-stimulatory pathway and,
therefore, C6 cells were treated with a combination of
FAKi with CNTF or IL-6. However, IL-6 and CNTF were
unable to further boost FAKi-mediated CNTF induction
(Figure 4F). Finally, under the same treatment conditions,
FAKi reduced phosphorylation of STAT3 (Tyr-705) most
notably in the presence of IL-6 (Figure 4G), suggesting
that FAK can activate STAT3 (Tyr-705), in addition to ac-
tivating the inhibitory STAT3 (Ser-727).
FAKi treatment induces CNTF and neurogenesis in the
adult CNS
The FAK inhibitor PF573228 injected directly into the
adult mouse striatum or spinal cord 4 hours later caused a
large decrease in pFAK (Figure 5A) and increase in CNTF
protein expression (Figure 5B). Control (vehicle only)
injected mice contained virtually undetectable levels of
CNTF, indicating an essentially complete repression under
physiological conditions and a rapid and robust increase
after FAK inhibition. Separately, adult mice were injected
systemically (i.p.) daily over three days with one of two
FAK inhibitors. PF573228 induced CNTF mRNA ~1.8
and ~1.4 fold in the spinal cord and SVZ, respec-
tively (Figure 5C). A second FAK inhibitor, FAK14, in-
duced CNTF expression ~1.9 and 1.4 fold, respectively
(Figure 5C).
Endogenous CNTF stimulates normal neuroblast for-
mation from the SVZ [4,5]. SVZ lysates from the mice that
were injected systemically over a three day period showed
that the proliferative marker Ki67 was upregulated 30% by
each of the FAK inhibitors (Figure 6A). Expression of epi-
dermal growth factor receptor (EGFR), a marker for tran-
sient amplifying progenitor SVZ cells [59], was similarly
Figure 4 STAT3 inhibition mediates CNTF repression by FAK. A) FAK inhibition reduces STAT3 phosphorylation on its inhibitory residue
(s727) as shown in western blots of C6 cells incubated for 4 hours. Total STAT3 antibodies were used as internal controls. B) Pre-incubation with
a STAT3 antagonist reduced the CNTF-inducing effects of FAK inhibitor in C6 cells. Thus, FAK represses CNTF by inhibiting STAT3. An AP1
transcription factor antagonist was without effect. Data are fold compared to control (not shown) and means +/−SEM. C) STAT3 binds the CNTF
promoter region of C6 cells as shown by ChIP analysis. STAT3 antibody immunoprecipitates (IP) CNTF promoter DNA as shown by the PCR
amplification products of two promoter-specific primer sets. Normal rabbit IgG was used as control for non-specific binding. Histone H3 was a
positive control. D) Sequencing of the amplification products of the STAT3 immunoprecipitate gave the predicted DNA regions. Key: Consensus
STAT3 binding sites; : CNTF initiation site; CNTF1 primer set (FWD, REV); CNTF 2 primer set (FWD, REV); < > denote DNA regions
excluded from this panel for presentation purposes. E) IL-6 treatment of C6 cells for 15 minutes robustly increased phosphorylation of STAT3 at
the Tyr-705 residue (y705) with modest increases after CNTF and LIF as shown by western blot. Ser-727 phosphorylation (s727) or total STAT3
(tSTAT3) was not affected. Similar results were seen at 4 hours. The blot is representative of 4 independent experiments. F) IL-6 induced only an
~10% increase in CNTF mRNA expression in C6 cells after 4 hours and did not augment FAKi-induced CNTF expression (n = 3-4 each, p < 0.05).
G) FAK inhibition reduced phosphorylation of STAT3 (y705) in C6 cells most notably under IL-6 treated conditions. Antibodies against total STAT3
were used as internal controls for western blots. Results were repeatable in independent experiments.
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tor PF573228 caused a 56% increase in the number of
SVZ neuroblasts stained for their marker doublecortin
(DCX; Figure 6B), confirming that neurogenesis was
induced. The SVZ clearly was thicker after systemic FAK
inhibitor treatment, representing more DCX cells as
shown in confocal images (Figure 6C).
Discussion
Astrocytes express a number of integrins [60] which are
well-known for roles in cell morphology and adhesion
[37,61-63], including αvβ5 integrin. This study identifies
an αvβ5 integrin signaling pathway that regulates gene
transcription, inhibiting glial CNTF expression. We can-
not rule out that other integrins also repress CNTF as we
did not block all integrin subunits, specifically αvβ8. How-
ever, astrocytes respond differently to vitronectin via αvβ5
and αvβ8 integrin [61], suggesting that they activate differ-
ent signaling pathways. Also, adult astrocytes lack αvβ8
integrin [37]. Our data show selectivity of integrins in
regulating CNTF, where blockade of αv and β5, but not α6
or β1 subunits induced CNTF expression in astroglioma
cells. Cell-cell contact enables cultured astrocytes to sup-
port oligodendrocyte survival through the α6β1, but notother integrins [64]. Thus, individual integrins have spe-
cific roles for regulating gene expression.
CNTF is a member of a cytokine family, including pro-
inflammatory interleukin-6 (IL-6), that also signal through
the gp130 receptor [32,33]. T-cell adhesion induces IL-6
in cultured astrocytes through activation of α3β1 integrin
[65]. Stretch-induced IL-6 expression in endothelial cells
is mediated by α5β1 integrin [66]. Thus, two closely re-
lated cytokines are regulated by different integrins and in
opposite directions, perhaps representing a mechanism by
which astrocytes coordinate responses to pathological
conditions. Neuronal BDNF and NGF are also upregulated
by RGD-integrin signaling [67], endothelial BDNF by β1
integrins [68], and IGF-1 by α2β1 and α11β1 integrins
[69]. Thus, compared to other neurotrophic factors,
CNTF seems to be unique in being repressed by integrins.
This explains its very low level of expression in the brain
compared to other neurotrophic factors.
Collectively, our data suggest that the CNTF-repressing
integrin signaling pathway contains FAK and JNK which
inhibits the transcription factor STAT3 (Figure 7). FAK
promotes FGF2-induced migration of astrocytes [70] as
expected from focal adhesions [71]. This study extends
the role of glial FAK to gene regulation. Neurons also con-
tain FAK [72] and in the adult, it is important for LTP [73]
Figure 5 FAK inhibition induces CNTF expression in the adult
CNS in vivo. A) Intracerebral injection of the FAK inhibitor PF573228
directly in the striatum of mice results in increased CNTF protein
4 hours later as shown in western blots. FAK activity was greatly
decreased as shown by lack of phosphorylation. (pFAK). α-tubulin =
internal control. Lanes are from individual animals. B) Similar results
were obtained after direct injection into the spinal cord. C) Systemic
intraperitoneal injections of the FAK inhibitors PF573228 or FAK14
induce CNTF mRNA in the spinal cord or SVZ relative to vehicle only
injected mice (Ctrl). Drugs were given 3 times every 24 hours and
tissues collected 2 hours after the last injection. Data are fold
change compared to control (Ctrl) and are means +/− SEM from 3–
4 mice per group.
Keasey et al. Cell Communication and Signaling 2013, 11:35 Page 7 of 15
http://www.biosignaling.com/content/11/1/35and plasticity [74]. FAK is largely unphosphorylated in the
adult brain [75] and activated pFAK immunostaining ap-
pears highest in neurons [76]. Thus, astroglial FAK may
be more responsive to inhibitors than neurons perhaps
explaining why the FAK-treated mice did not have obvious
behavioral changes. Clinical trials for cancer with FAK
inhibitors which reach the CNS suggest that they are
well-tolerated. Even so, it will be important to define the
effects of chronic treatment with FAK inhibition on
CNS function.Here, JNK had a selective role in repressing CNTF
whereas other major pathways downstream from FAK did
not seem to be involved, i.e., ERK and p38 [48,77]. In
contrast, FAK-driven JNK and ERK both regulate FGF2-
induced astroglial migration [70]. The NF-kappaB path-
way mediates α3β1 and α5β1 integrin stimulation of IL-6
in astrocytes [65] and endothelial cells [66]. These in-
tegrins do not regulate CNTF. Moreover, NF-kappaB is
downstream of integrin linked kinase, which associates
with β1 and β3 integrins [78], neither one of which regu-
lates CNTF. Vitronectin activation of αvβ3 integrin in
astrocytes signals through PKCα and RhoA, downstream
of FAK [62]. However, these molecules probably do not
repress CNTF as αvβ3 integrin does not either. Therefore,
the JNK pathway may specifically repress CNTF, perhaps
mediating the effects of vitronectin through αvβ5 but not
αvβ3 integrin.
The transcription factor Sox10 is a potent positive regu-
lator of CNTF gene transcription in Schwann cells [30].
However, in the CNS, Sox10 is specific to oligodendro-
cytes [79] and is not induced in reactive astrocytes [80]. It
remains to be determined whether other Sox family mem-
bers regulate CNTF in astrocytes. In cultured astrocytes,
the CNTF promoter is also accessible to Peroxisome
Proliferator-Activated Receptor gamma (PPAR-γ) in asso-
ciation with cAMP Response Element Binding (CREB)
and Activating Transcription Factor 2 (ATF2) [81]. In-
duction of CNTF by these transcription factors was
dependent upon nitric oxide mediated p38 MAPK activity.
We propose that the gp130-JAK-STAT3 pathway is an
additional pathway activating CNTF transcription in as-
trocytes, but that the FAK pathway chronically inhibits
STAT3 at the Ser-727 residue (Figure 7), providing new
insight into co-regulation by integrins and cytokine recep-
tors. FAK inhibition robustly induced CNTF while causing
a large reduction in pJNK and pSTAT3 (Ser-727), reveal-
ing a novel integrin-STAT3 link. JNK can phosphorylate
STAT3 at this inhibitory site [51] and pSTAT3 (Ser-727)
can have reduced transcriptional activity [82,83]. In appar-
ent contrast, pSTAT3 (Ser-727) can cause stable STAT3-
STAT3 DNA binding activity [84]. It is possible that
pSTAT3 (Ser-727) has gene specific interactions similar to
methyl CpG binding protein 2 which can inhibit [85] or
activate transcription when associated with other tran-
scription factors [86]. In astrocytes, CNTF induces phos-
phorylation of STAT3 at Tyr-705 for transcriptional
activity in vitro [9,87-90] and in vivo [91]. C6 glioma cells
reportedly do not express the CNTF alpha receptor [92]
but can respond to CNTF [93], possibly through the IL-6
receptor to activate JAK-STAT3 (Tyr-705) signaling as
shown in BaF3 cells [94]. In our hands, CNTF along with
LIF only slightly activated STAT3 (Tyr-705) in C6 cells,
whereas IL-6 had robust effects. This suggests that the
gp130 receptor and not the LIFβR required for LIF
Figure 6 Systemic FAK inhibitor treatment increases adult CNS neurogenesis. A) mRNA for the proliferation marker Ki67 and the marker for
proliferating neural C cell progenitors, EGFR, increased in the SVZ after systemic FAK inhibitor PF573228 treatment in mice. CNTF mRNA was
increased in the same extracts (Figure 6C). Drugs were given 3 times every 24 hours and tissues collected 2 hours after the last injection. Data are
mean fold change compared to vehicle treated mice +/− SEM, n = 3–4 mice. B) In other mice, the systemic injections of FAK inhibitor PF573228
(n = 6) increased the number of DCX + neuroblasts in the SVZ. Data are expressed as a mean percentage of vehicle (n = 4) treated mice +/− SEM.
C) Representative confocal images of the dorsal SVZ showing increased numbers of nuclei (Hoechst) and neuroblasts (dcx) in an FAK inhibitor-
injected mouse compared to a vehicle-injected mouse. Scale bar = 20 μm. CC = corpus callosum, LV = lateral ventricle, STR = striatum.
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of STAT3 is also consistent with our finding that IL-6 and
CNTF increase CNTF expression in astrocytes of the
adult brain [18] and that STAT3 binds the CNTF pro-
moter. This feed-forward autoregulation by CNTF is
present in the retina [12] and in astrocyte and C6
astroglioma cell cultures [36].
Despite the robust activation of STAT3 (Tyr-705) by IL-
6 in C6 cells the increase in CNTF mRNA was only 10%.
This suggests that the integrin-mediated inhibitor signal-
ing “brake” is the strongest factor in determining levels of
CNTF expression. In fact, IL-6 could not further increase
FAKi-induced CNTF expression despite the presence of
increased STAT3 (Tyr-705) compared to FAKi alone.
Interestingly, FAKi reduced STAT3 (Tyr-705) phosphoryl-
ation. Identification of the intermediary signaling mole-
cules that link FAK to STAT3 (Tyr-705) will require
further study. This dual integrin-related mechanism to
regulate CNTF indicates that CNTF is a highly regulated
gene which is only modulated slightly under normal
physiological conditions. Under pathological conditionsCNTF may be greatly induced by the loss of cell-cell con-
tact, immediately releasing the inhibitory STAT3 pathway
independent of expression of cytokines, perhaps helping
to make this a rapid first-responder system. The complete
loss of contact, however, and therefore FAK stimulation of
STAT3 (Tyr-705) might reduce the potency of other
growth factors that signal through the STAT3 pathway.
Interestingly, STAT3 independently from its transcrip-
tional function is necessary to maintain normal mito-
chondrial bioenergetic function, which is dependent on
Ser-727 whose phosphorylated form is highly enriched in
mitochondria [95,96]; reviewed in [97]. This mechanism is
also present in cortical astrocytes [98]. In light of our
findings, it is possible that integrin ligand binding pro-
motes mitochondrial function through FAK-JNK-mediated
STAT3 (Ser-727) phosphorylation. Whether and how the
mitochondrial effects of STAT3 might affect CNTF ex-
pression remains to be determined. CNTF has also re-
cently been found to normalize mitochondrial function in
diabetic conditions [99]. This raises the possibility that
under pathological conditions that reduce Ser-727 activity,
Figure 7 Schematic representation of the proposed pathways
that regulate astroglial CNTF. This study identifies an inhibitory
pathway (Red) where ligands such neuronal Thy-1 bind to astrocyte
αvβ5 integrin resulting in FAK phosphorylation. Subsequently, JNK is
activated and phosphorylates STAT3 at an inhibitory serine-727
(s727) residue potently repressing transcription of CNTF. Conversely,
the CNTF-stimulatory pathway is activated by neural cytokines such
as CNTF, LIF and IL-6 which bind to their respective gp130 (gp)
receptor complexes (CNTF: CNTFαR/LIFβR/gp130; LIF: LIFβR/gp130;
IL-6: IL-6αR/gp130/gp130; Lβ indicates LIFβR), triggering recruitment
of JAK to activate STAT3 by phosphorylation at the pro-transcription
residue tyrosine-705, y705; Green). CNTF is known to activate STAT3
in astrocytes in vitro [9,87-90] and in vivo [91]. FAK may
simultaneously stimulate the activating pathway, potentially
representing another component of the tightly regulated CNTF
gene expression under physiological conditions.
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chondrial function.
The function of CNTF continues to be elucidated
with evidence of its role extending to stimulation of
mitochondrial bioenergetic function via NF-kB signal-
ing [99] as well as regulating neurogenesis [18] and
neuroprotection [19]. With such diverse functions and
as a mediator of critical protective STAT3 signaling in
neurons [90], it is likely that several molecular mecha-
nisms exist that lead to CNTF transcription.
The role of neural Thy-1 is poorly understood despite
being highly enriched in the brain and exclusively present
on neurons [100]. We identify Thy-1 as one of the neur-
onal ligands that mediates contact-dependent repression
of CNTF in astrocytes. This is consistent with the finding
that Thy-1 increases 100 fold during early post natal de-
velopment in the CNS [24] when CNTF expression stays
low, whereas it increases greatly in the peripheral nervous
system during a similar time frame [15]. Thy-1 binds to
astrocytic αvβ3 integrin to activate FAK resulting in mor-
phological changes and cell-cell attachment [62,71]. Thy-1
can bind directly to αvβ5 integrin in lung fibroblasts [26],
consistent with our findings that αvβ5 integrin repressesCNTF and Thy-1 inhibition increases CNTF. Neuronal
loss in the adult mouse brain induces CNTF within hours
[18] possibly by disinhibition of Thy-1. It remains to be
determined whether the other integrin substrates which
inhibited CNTF expression in vitro play a similar role in
the CNS. Laminin is produced by astrocytes [101] and
neurons [6], vitronectin by endothelial cells [42] and fibro-
nectin is associated with astrocytes [43].
FAK plays key roles during nervous system development
[75] but its role and that of downstream JNK in adult
neurogenesis had not been investigated. Importantly, in-
hibition of FAK with systemic drugs rapidly induced
CNTF protein expression which was biologically active as
suggested by the increased formation of new neuroblasts
in the adult mouse SVZ. This is consistent with our find-
ings that endogenous CNTF enhances proliferation of
progenitors in the SVZ without affecting normal neuronal
cell fate choice [4,5]. Our data are also consistent with the
finding that SVZ neurogenesis is dependent on STAT3
[102]. Our finding that CNTF expression is higher in the
SVZ than most other brain regions [5] is consistent with
the absence of neuronal Thy-1 in the SVZ and RMS
(Allen Brain Atlas, [www.brain-map.org]). This may allow
CNTF-induced proliferation until the neuroblasts reach
their target in the olfactory bulb which is rich in Thy-1.
Integrins such as α6β1, αv and β8, and ligands such as
laminin, play a key role in neuroblast migration [103-108].
Little is known about gene regulation by integrins in the
SVZ. Interestingly, α6 blocking antibodies increased SVZ
proliferation in vivo [106], suggesting that there is an
additional growth factor which is repressed by laminin.
Conclusion
Our data suggest that FAK inhibition rapidly induces
CNTF protein expression from very low levels within four
hours in vivo. This is consistent with our finding that
CNTF mRNA doubles within one hour after stroke to
serve a neuroprotective role [18]. Consistent with the
current data, blockade of integrins with RGD peptides re-
duced pFAK and decreased infarct area in a rodent model
of stroke [76]. We propose that this integrin-FAK pathway
constitutes a sensitive neuroglial sensor for regulating
neurotrophic support or neuronal function in the CNS.
This study also opens up avenues for pharmacologically
stimulating and utilizing the neuroprotective actions of
endogenous CNTF in neurological diseases, thus cir-
cumventing the low CNS bioavailability and systemic side
effects of systemic administered CNTF [14].
Methods
All procedures involving animals were carried out in ac-
cordance with NIH guidelines and approved by the Uni-
versity of Louisville Institutional Animal Care and Use
Committee (IACUC). Data are shown as average ± SEM.
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C6 astroglioma cells were obtained from ATCC and were
maintained in in t75 culture flasks (USA Scientific)
in DMEM supplemented with 10% Fetal Calf Serum,
1 mM L-Glutamine, 100 U Penicillin and 100 μg Strepto-
mycin (All Gibco). Cells were passaged every three days
after washing with PBS and incubation with 0.05% trypsin:
Hanks Balanced Salt Solution for 2 minutes. After centrifu-
gation, cell pellets were resuspended in fresh medium,
plated at 160,000 ml-1 and maintained for 24 hours except
where noted. C6 cells were only used between passage
number 10–40.
To test effects of ECM ligands C6 cells were cultured for
4 hours on poly-d-lysine (50 μg/ml; Sigma, USA) coated
multi-well culture plates (6 well, Corning) coated with
vitronectin (50 μg/ml, #SRP3186), laminin (50 μg/ml,
#L2020), fibronectin (50 μg/ml, #F3667), thrombospondin
(0.25 μg/cm2, #SRP4805), fibrinogen (50 μg/ml #F3879) or
collagen type I (100 μg/ml, #C5533, all Sigma) before isola-
tion of RNA. For antibody experiments, freshly plated C6
cells were incubated with neutralizing antibodies against
αv (5 μg/ml, #104108, Biolegend, UK; [109,110]), α6 (5 μg/
ml, #313614, Biolegend; [111]), β1 (5 μg/ml, #102210,
Biolegend; [112]) or β5 (5 μg/ml, #12-0497-41, eBio-
sciences, USA; [113,114]) integrins or IgG control (5 μg/
ml, #402014, Biolegend) for 4 hours before isolating
RNA. Pharmacological antagonists against JNK (SP600125;
25 μM; Sigma; [115]), p38 (SB203580;10 μM; Tocris;
[116]), ERK (SL327, 50 μM; Tocris; [117]) or FAK
(PF573228; 10 μM; Tocris; [118]) were incubated with C6
cells for 4 hours, 24 hours after initial plating. To block
STAT3 activation, the selective small molecule inhibitor
Stattic (10 μM; Tocris; [52]) was incubated with C6 cells
1 hour before addition of FAKi (PF573228). To block AP-1
activity C6 cells were incubated with the AP-1 antagonist
SR11302 (10 μM; Tocris; [119,120]) 1 hour prior to co-
incubation with FAKi (PF573228). We did not include
negative controls for these inhibitors because most of the
drugs used in this study are relatively well studied and elu-
cidated and also, we do not know of the existence of in-
active enantiomers for PF573228. The drugs which lacked
effects on CNTF expression may serve as negative controls
for the ones that did have an effect.
Primary astrocyte-neuron co-cultures were performed as
described before from the cortices of neonatal C57BL/6
mice [18]. Neurons (0.5 × 106/ml) were incubated with
Thy-1 neutralizing antibodies (5 μg/ml; #105309, Biolegend;
[121]) or isotype IgG control (5 μg/ml; #402014, Biolegend)
before seeding onto the astrocytes or poly-D- lysine-coated
plates. RNA was isolated after 24 hours.
In vivo injections
Stereotaxic injection into the striatum of anesthetized
mice was performed as described [18] through a glassneedle with a 35 μm diameter tip attached to a pico
spritzer (Parker Instrumentation) and loaded with either
vehicle (75% DMSO in saline) or 20 μg PF573228
(Cat#3239, Tocris) in vehicle. One day later, the mice were
transcardially perfused with ice cold PBS, the striatum dis-
sected and flash frozen at −80°C. To inject in the spinal
cord, the vertebral column was stabilized in a frame, the
cord exposed with a laminectomy at thoracic level 9 and
the dura incised. A volume of 1 μl containing vehicle or
20 μg PF573228 was injected into the middle of the cord.
After 4 hours, mice were transcardially perfused, and a
3 mm section of cord with the injection site in the middle
was dissected and flash frozen.
Systemic i.p. injections of FAK inhibitors were applied
daily over three days with 30 mg/kg/day PF573228
dissolved in 100 μl of 75% DMSO or 30 mg/kg/day FAK14
(Cat#3414; Tocris), dissolved in 100 μl PBS. The brains of
these mice were collected 2 hours after the last injection
and processed for measuring CNTF mRNA levels. Other
mice were processed for histology as described further on.
Quantitative-RT-PCR
Total RNA was extracted from tissue and cells with the
miRVana RNA isolation kit (Ambion) according to manu-
facturer’s protocol. RNA concentration was measured with
a nano-drop Spectrophotometer. Quantitative Real Time
RT-PCR (qPCR) was performed as described [18] with
some minor alterations. Briefly, 0.5 μg of RNA was treated
with DNAse to destroy contaminating DNA according to
standard procedure. DNAse was inactivated before RNA
was used to generate cDNA. Complimentary DNA was
generated from 0.5 μg of RNA using MMLV reverse tran-
scriptase (200 U), 0.5 μg random hexamers, 0.5 mM dNTP
mix in a 25 μl reaction. Reactions were incubated for one
hour at 37°C. The cDNA was then used with Applied
Biosytems qRT-PCR primer sets specific to mouse CNTF
(mM00446373_m1), GAPDH (mM4352339E), EGFR
(mM00433023) and Ki67 (mM01278606) and rat primer
sets were CNTF (Rn00755092) and GAPDH (Rn99999916;
all Applied Biosystems). PCR reactions were performed
using the TaqMan Gene Expression Master Mix (4369016,
Applied Biosystems) with the following cycling parameters:
10 minutes at 95°C followed by 40 cycles of; 95°C for
15 sec; 60° for 1 minute in an ABI 7900 Thermal Cycler
(Applied Biosystems). Data analysis was performed with
the ΔΔCt method with GAPDH serving as an endogenous
control.
ChIP analysis
ChIP analysis was performed with the Millipore ChIP kit
(#17-294, Millipore, USA) according to the manufacturer’s
protocol with some minor modifications. A total of 2.56
million C6 cells were plated at 160,000 cells/ml in 75 cm2
flasks for 24 hours, then treated with vehicle (75% DMSO)
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Tocris) for 4 hours. C6 cells were fixed with 1% formal-
dehyde for 10 minutes at room temperature and then
washed with and resuspended in ice cold PBS sup-
plemented with a protease inhibitor cocktail (Cat# P8340,
Sigma). Cells were scraped and centrifuged at 4°C for 5
minutes at 2,000 rpm, after which the cell pellet was
resuspended in 1x SDS lysis buffer and left on ice for
10 minutes. Chromatin was sheared by sonication
(Misonix, XL-2000) on ice (six pulses of 10 seconds at a
setting of 3) to an average size of sheared chromatin of
500 bp and up to ~1.5-2 Kbp. Sonicated samples were
centrifuged for 10 minutes at 14,000 rpm at 4°C to remove
any debris, and the supernatant was divided into 200 μl al-
iquots containing material from 1 million cells for each
ChIP analysis, and then snap frozen and stored at −80°C.
ChIP grade rabbit polyconal antibodies were against
STAT3 (#9132, Cell Signaling, USA) or for normalization,
Histone H3 (ab1791, Abcam, UK). Normal rabbit IgG
(Cat#2729, Cell Signaling) was used as a control for non-
specific binding. Immunoprecipitation was performed
according to manufacturer’s protocol. Chromatin precipi-
tated DNA was resuspended in a final volume of 40 ul of
water (both for IP samples and input samples) and 1/10th
of each was used for the PCR amplification. Primers were
(Forward; Reverse): CNTF primer set 1 starting at 25 bp
upstream from the CNTF initiation site (P3), 5'-
AATCCACAGCCAGGAATTTG-3' and 5'-GATTCCAT
AAGAGCAGTCAGGTC-3', and CNTF primer set 2
starting at 1425 bp (P6), 5'-AAGAGTTGGGAAGC
GCTGCTAATG-3' and 5'-TGCCGTAGAACTGGCAA
GGTTAGA-3'; cMyc; a known target of STAT3 mediated
transcription [122] and in C6 glioma cells [123] was 5′-
GTCAACATAGCTGTACGCCCAAACGC-3′, and 5′-G
TTATGTAGGAGCCCTTGCTCAGTGTG-3′. Reactions
were prepared in a final volume of 20 μl with 1x PCR buf-
fer, 200 μM dNTP, 1.5 mM MgCl2, 0.5 μM each forward
and reverse primers, 1/10 chromatin immunoprecipitated
(or Input) DNA sample and 0.5 U of Taq DNA polymer-
ase. The PCR cycle used were 3 minutes at 94°C for the
initial denaturation, 36 cycles of 45 seconds of 94°C,
30 seconds at 60°C, 60 seconds at 72°C, followed by 10
minutes at 72°C. ChIP amplification products were se-
quenced at the University of Louisville DNA Core Facility.
Western blotting
Protein lysate from cell cultures was isolated using RIPA
buffer (50 mM Tris–HCl, 1% [w/v] Tergitol, 0.25% [w/v]
Sodium deoxycholate, 150 mM NaCl and 100 mM EDTA)
supplemented with 1 mM sodium orthovanadate, 5 mM
sodium fluoride and 0.1% [v/v] protease inhibitor cocktail.
Cells were washed in ice cold PBS (Gibco) before cells
were scraped from the surface with an inverted p1000 pip-
ette tip in RIPA buffer. Lysate was transferred toEppendorf tubes and placed on ice. The lysate was then
triturated using a 1 ml syringe (BD) and 26½ gauge needle
before samples were returned to ice and incubated for
30 minutes. Samples were centrifuged at 12,300 rpm at
4°C for 15 minutes. Lysate was then transferred to fresh
Eppendorf tubes and stored at −80°C or prepared for pro-
tein quantitation with Pierce’s BCA protein assay as per
manufacturer’s instructions. Proteins were separated by
SDS-PAGE and blotting was then performed with speci-
fic antibodies for CNTF (1:400; MAB338, Millipore), or
with FAK (1:1000; Cat#3285), pFAK-Tyr397 (1:1000;
Cat#3283), JNK (1:1000; Cat#3708), pJNK-Tyr185 (1:1000;
Cat#9251), pSTAT3-Ser727 (1:500; Cat#9134), pSTAT3-
Tyr705 (1:1000; Cat #9145). Concentration used was
1/1000 STAT3 (1:1000; Cat#9132), αTubulin (1:2000;
Cat#2125), all from Cell Signaling Technology. Briefly,
after transfer, PVDF membranes were blocked in 5% non-
fat milk in Tris buffered saline with 0.05% tween (TBST)
for 1 hour then incubated overnight (4°C) in primary anti-
body (5% milk:TBST). Blots were washed with TBST
before incubation (2 hours; room temperature) with
appropriate Horse Radish Peroxidase conjugated second-
ary antibodies (anti-mouse, Cat#7076 and anti-rabbit,
Cat#7074, Cell Signaling) in 5% milk; TBST. Blots were
washed and ECL substrate used to visualize antibodies
according to standard procedures.Immunocytochemistry
Mice were transcardially perfused with ice-cold PBS
followed by 4% paraformaldehyde. Their brains were
extracted, post-fixed overnight and cryoprotected in 30%
sucrose in PB for 24 hours. Coronal 30 μm thick sections
were cut on a sliding freezing microtome. Starting at a
random point along the rostrocaudal axis of the brain,
every sixth section through the SVZ was immunostained
for doublecortin (dcx) to detect neuroblasts. Briefly, sec-
tions were incubated in 5% donkey for 1 hour followed by
overnight incubation (4°C) with goat anti-DCX (1:500,
SC8066, Santa Cruz). Secondary antibodies were anti-goat
IgG (1:500, Alexa Fluor 488, A11055, Invitrogen) for
1 hour at room temperature. Sections were incubated with
Hoechst (1 μg/ml) before cover slipping for imaging. Con-
focal images were taken on a Nikon D-Eclipse C1 confocal
microscope. The images of 1024 × 1024 x-y pixel and
8.4 μm z-stack were taken using a 100x oil objective.Cell counting and statistical analysis
The number of neuroblasts was counted independently
by two investigators blinded to the treatment using a
20x objective (Leica DM6000 microscope) by identifying
dcx-positive cells with Hoechst-labeled nuclei in the
most populated dorsal quadrant of the SVZ. Cells were
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box) overlaying the entire width of the SVZ using 4 sec-
tions per brain. Statistical analyses were performed with
Student’s t test or One Way Analysis of Variance
(ANOVA) with a Dunnett’s or Bonferroni post-hoc test
where noted. A value of p < 0.05 considered as statisti-
cally significant.
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